NCT00807534

Brief Summary

This study was designed to test the following hypothesis: The 3-min constant rate step test and the 3-min constant rate shuttle walk test will be sensitive to detect improvement in exertional dyspnea following acute bronchodilation in patients with COPD.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable chronic-obstructive-pulmonary-disease

Timeline
Completed

Started Oct 2008

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2008

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 10, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 12, 2008

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2009

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2010

Completed
Last Updated

February 9, 2011

Status Verified

May 1, 2010

Enrollment Period

1.2 years

First QC Date

December 10, 2008

Last Update Submit

February 7, 2011

Conditions

Keywords

Chronic Obstructive Pulmonary Disease (COPD)Exercise3-min constant rate stepping test3-min constant rate walking testBronchodilationIpratropium bromide

Outcome Measures

Primary Outcomes (1)

  • Dyspnea at the end of the 3-minute walking and stepping exercises

    at the end of the 3-minute exercises

Study Arms (2)

ipratropium bromide

ACTIVE COMPARATOR

acute bronchodilation: ipratropium bromide

Drug: ipratropium bromideBehavioral: constant rate step testBehavioral: constant rate shuttle walk test

placebo

PLACEBO COMPARATOR

placebo nebulization

Drug: placeboBehavioral: constant rate step testBehavioral: constant rate shuttle walk test

Interventions

ipratropium bromide nebulization

Also known as: Atrovent
ipratropium bromide

placebo nebulization

placebo

nebulization of 500ug

Also known as: Atrovent
ipratropium bromideplacebo

nebulization of 500ug

Also known as: Atrovent
ipratropium bromideplacebo

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age \> 50 years
  • smoking history \> 10 packs/year
  • post-bronchodilator FEV1 between 30 and 80% predicted and FEV1/FVC \< 70% as assessed in previous pulmonary function test (GOLD stage II and III)

You may not qualify if:

  • respiratory exacerbation within the preceding 2 months
  • history of asthma
  • significant O2 desaturation (SaO2 \< 85%) at rest or during exercise
  • presence of another pathology that could influence exercise tolerance

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Hélène Perrault

Montreal, Quebec, Canada

Location

François Maltais

Québec, Quebec, G1V4G5, Canada

Location

Related Publications (1)

  • Sava F, Perrault H, Brouillard C, Darauay C, Hamilton A, Bourbeau J, Maltais F. Detecting improvements in dyspnea in COPD using a three-minute constant rate shuttle walking protocol. COPD. 2012 Aug;9(4):395-400. doi: 10.3109/15412555.2012.674164. Epub 2012 Apr 18.

MeSH Terms

Conditions

Pulmonary Disease, Chronic ObstructiveMotor Activity

Interventions

Ipratropium

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsBehavior

Intervention Hierarchy (Ancestors)

Atropine DerivativesTropanesAzabicyclo CompoundsAza CompoundsOrganic ChemicalsBelladonna AlkaloidsSolanaceous AlkaloidsAlkaloidsHeterocyclic CompoundsBridged Bicyclo Compounds, HeterocyclicHeterocyclic Compounds, Bridged-Ring

Study Officials

  • François Maltais, MD

    Laval University

    PRINCIPAL INVESTIGATOR
  • Hélène Perrault, Ph.D.

    McGill University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
DIAGNOSTIC
Intervention Model
CROSSOVER
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 10, 2008

First Posted

December 12, 2008

Study Start

October 1, 2008

Primary Completion

December 1, 2009

Study Completion

June 1, 2010

Last Updated

February 9, 2011

Record last verified: 2010-05

Locations